CELU Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of -173.17% compared to Celularity's net margin of 8.48%. Celularity's return on equity of -118.79% beat Eli Lilly and's return on equity of 66.4%.

Celularity has a consensus price target of --, signalling upside risk potential of 1016.07%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 25.65%. Given that Celularity has higher upside potential than Eli Lilly and, analysts believe Celularity is more attractive than Eli Lilly and.

Celularity has a beta of 0.642, which suggesting that the stock is 35.812% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.409, suggesting its less volatile than the S&P 500 by 59.07%.

Celularity has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.30 per share. Celularity pays -- of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Celularity quarterly revenues are $9.3M, which are smaller than Eli Lilly and quarterly revenues of $11.4B. Celularity's net income of -$16.1M is lower than Eli Lilly and's net income of $970.3M. Notably, Celularity's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 84.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Celularity is 0.98x versus 17.33x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -173.17% compared to Celularity's net margin of -49.65%. Celularity's return on equity of -118.79% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Celularity has a consensus price target of --, signalling upside risk potential of 1016.07%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 546.03%. Given that Celularity has higher upside potential than NovaBay Pharmaceuticals, analysts believe Celularity is more attractive than NovaBay Pharmaceuticals.

Celularity has a beta of 0.642, which suggesting that the stock is 35.812% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Celularity has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Celularity pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Celularity quarterly revenues are $9.3M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Celularity's net income of -$16.1M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Celularity's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Celularity is 0.98x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -173.17% compared to Celularity's net margin of -2357.27%. Celularity's return on equity of -118.79% beat Palatin Technologies's return on equity of --.

Celularity has a consensus price target of --, signalling upside risk potential of 1016.07%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1431.53%. Given that Palatin Technologies has higher upside potential than Celularity, analysts believe Palatin Technologies is more attractive than Celularity.

Celularity has a beta of 0.642, which suggesting that the stock is 35.812% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Celularity has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Celularity pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Celularity quarterly revenues are $9.3M, which are larger than Palatin Technologies quarterly revenues of $350K. Celularity's net income of -$16.1M is lower than Palatin Technologies's net income of -$7.8M. Notably, Celularity's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Celularity is 0.98x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Dentsply Sirona has a net margin of -173.17% compared to Celularity's net margin of -51.95%. Celularity's return on equity of -118.79% beat Dentsply Sirona's return on equity of -13.34%.

Celularity has a consensus price target of --, signalling upside risk potential of 1016.07%. On the other hand Dentsply Sirona has an analysts' consensus of $22.96 which suggests that it could grow by 21.25%. Given that Celularity has higher upside potential than Dentsply Sirona, analysts believe Celularity is more attractive than Dentsply Sirona.

Celularity has a beta of 0.642, which suggesting that the stock is 35.812% less volatile than S&P 500. In comparison Dentsply Sirona has a beta of 0.965, suggesting its less volatile than the S&P 500 by 3.545%.

Celularity has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dentsply Sirona offers a yield of 3.38% to investors and pays a quarterly dividend of $0.16 per share. Celularity pays -- of its earnings as a dividend. Dentsply Sirona pays out -87.88% of its earnings as a dividend.

Celularity quarterly revenues are $9.3M, which are smaller than Dentsply Sirona quarterly revenues of $951M. Celularity's net income of -$16.1M is higher than Dentsply Sirona's net income of -$494M. Notably, Celularity's price-to-earnings ratio is -- while Dentsply Sirona's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Celularity is 0.98x versus 1.00x for Dentsply Sirona. Usually stocks with elevated PS ratios are considered overvalued.